In this segment on relapsed multiple myeloma, Luciano Costa invites panelists to interpret key efficacy findings from the phase 3 MajesTEC-3 study evaluating a BCMA-directed bispecific antibody in combination with daratumumab and dexamethasone. Carol Ann Huff and Muhamed Baljevic highlight the depth and durability of response as particularly notable, including improvements in progression-free survival compared with established standard-of-care regimens. They emphasize that these outcomes are especially relevant in patients with prior exposure to anti-CD38 therapy and lenalidomide, a population often associated with less favorable outcomes. The panel also discusses how these findings fit within evolving treatment paradigms, where achieving deeper responses earlier in relapse may influence long-term disease control. Overall, the discussion underscores the clinical significance of these data while reinforcing the importance of interpreting results within the broader multiple myeloma treatment landscape.
